1. Home
  2. IRMD vs MLYS Comparison

IRMD vs MLYS Comparison

Compare IRMD & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IRMD

iRadimed Corporation

N/A

Current Price

$82.93

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$28.15

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IRMD
MLYS
Founded
1992
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
2.5B
IPO Year
2014
2023

Fundamental Metrics

Financial Performance
Metric
IRMD
MLYS
Price
$82.93
$28.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$116.00
$48.67
AVG Volume (30 Days)
80.0K
1.1M
Earning Date
05-01-2026
05-06-2026
Dividend Yield
0.95%
N/A
EPS Growth
16.67
37.43
EPS
0.86
N/A
Revenue
$83,814,000.00
N/A
Revenue This Year
$12.38
N/A
Revenue Next Year
$11.31
N/A
P/E Ratio
$95.83
N/A
Revenue Growth
14.43
N/A
52 Week Low
$67.84
$22.30
52 Week High
$107.90
$47.65

Technical Indicators

Market Signals
Indicator
IRMD
MLYS
Relative Strength Index (RSI) 31.39 56.32
Support Level $76.95 $25.56
Resistance Level $88.93 $31.26
Average True Range (ATR) 2.09 1.56
MACD -0.18 0.21
Stochastic Oscillator 13.44 56.06

Price Performance

Historical Comparison
IRMD
MLYS

About IRMD iRadimed Corporation

iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: